Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Beam Therapeutics (BEAM) Enterprise Value (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Enterprise Value for 7 consecutive years, with -$1.2 billion as the latest value for Q4 2025.

  • On a quarterly basis, Enterprise Value fell 46.37% to -$1.2 billion in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.2 billion, a 46.37% decrease, with the full-year FY2025 number at -$1.2 billion, down 46.37% from a year prior.
  • Enterprise Value was -$1.2 billion for Q4 2025 at Beam Therapeutics, down from -$1.1 billion in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$156.5 million in Q3 2022 to a low of -$1.2 billion in Q4 2025.
  • A 5-year average of -$865.8 million and a median of -$1.0 billion in 2023 define the central range for Enterprise Value.
  • Peak YoY movement for Enterprise Value: surged 83.23% in 2022, then crashed 548.81% in 2023.
  • Beam Therapeutics' Enterprise Value stood at -$560.0 million in 2021, then plummeted by 92.53% to -$1.1 billion in 2022, then dropped by 10.36% to -$1.2 billion in 2023, then grew by 28.5% to -$850.7 million in 2024, then tumbled by 46.37% to -$1.2 billion in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Enterprise Value are -$1.2 billion (Q4 2025), -$1.1 billion (Q3 2025), and -$1.2 billion (Q2 2025).